Abstract: The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.
Abstract: The present invention relates to a solid composition including at least one hypothiocyanite (OSCN?) salt combined with a cation, wherein said solid composition is in the form of an amorphous and/or crystalline powder. The invention also relates to a method for producing said solid composition, and to the use thereof.
Type:
Grant
Filed:
October 10, 2012
Date of Patent:
December 16, 2014
Assignees:
Alaxia SAS, Stragen Pharma SA
Inventors:
Sandrine Perrotto, Sébastien Gluszok, Philippe Bordeau, Catherine David
Abstract: A solid composition is provided herein comprising at least one hypothiocyanite salt (OSCN—) of a cation in an amorphous and/or crystalline powder form. Also provided herein are methods of making the composition and methods of treating various conditions, such as airborne infection, lower respiratory tract infection or upper respiratory tract infection.
Type:
Grant
Filed:
October 10, 2012
Date of Patent:
October 21, 2014
Assignee:
Alaxia SAS
Inventors:
Sandrine Perrotto, Sébastien Gluszok, Philippe Bordeau
Abstract: A solid composition is provided herein comprising at least one hypothiocyanite salt (OSCN—) of a cation in an amorphous and/or crystalline powder form. Also provided herein are methods of making the composition and methods of treating various conditions, such as airborne infection, lower respiratory tract infection or upper respiratory tract infection.
Abstract: The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.
Abstract: The invention relates to an autonomous portable device for the storage of at least two formulations and for the automatic extemporaneous preparation of an active solution from the two formulations, said device comprising: a first compartment for containment of a first formulation, a second compartment for containment of a second formulation, a retaining chamber which communicates at least with the first compartment by means of at least one transfer channel and which comprises at least one outlet channel for the active solution, manually triggered mixing and expelling means suitable for, after triggering, automatically: bringing the two formulations into contact, and expelling, via the outlet channel, at least a part of the active solution at the end of a minimum reaction time.
Type:
Application
Filed:
January 28, 2010
Publication date:
September 2, 2010
Applicant:
ALAXIA
Inventors:
Philippe BORDEAU, Martin GUILLAUME, Marc COLLADO, Barbara LENOIR